



# Benign Prostat Hiperplazisinde Alfa Blokör Kullanımı ve Cinsel Fonksiyonlar

---

Yazar  
Ahmet Murat BAYRAKTAR



# **Benign Prostat Hiperplazisinde Alfa Blokör Kullanımı ve Cinsel Fonksiyonlar**

**Yazar**

**Ahmet Murat BAYRAKTAR**



© Copyright 2026

*Bu kitabın, basım, yayın ve satış hakları Akademisyen Kitabevi A.Ş. 'ye aittir. Anılan kuruluşun izni alınmadan kitabın tümü ya da bölümleri mekanik, elektronik, fotokopi, manyetik kağıt ve/veya başka yöntemlerle çoğaltılamaz, basılamaz, dağıtılamaz. Tablo, şekil ve grafikler izin alınmadan, ticari amaçlı kullanılamaz. Bu kitap T.C. Kültür Bakanlığı bandrolü ile satılmaktadır.*

Bu kitap "Benign Prostat Hiperplazisine Bağlı Alt Üriner Sistem Semptomu Olan Hastalarda Alfa Blokör Kullanımının Cinsel Fonksiyonlar Üzerine" adlı uzmanlık tezinden üretilmiştir.

<b>E-ISBN</b>	<b>Sayfa ve Kapak Tasarımı</b>
978-625-362-010-3	Akademisyen Dizgi Ünitesi
<b>Kitap Adı</b>	<b>Yayıncı Sertifika No</b>
Benign Prostat Hiperplazisinde Alfa Blokör Kullanımı ve Cinsel Fonksiyonlar	47518
<b>Editör</b>	<b>Baskı ve Cilt</b>
Özdem Levent ÖZDAL ORCID iD: 0000-0002-8747-8239	Vadi Matbaacılık
<b>Yazar</b>	<b>Bisac Code</b>
Ahmet Murat BAYRAKTAR ORCID iD: 0000-0002-4913-8698	MED016000
	<b>DOI</b>
	10.37609/akya.4142
<b>Yayın Koordinatörü</b>	
Yasin DİLMEN	

**Kütüphane Kimlik Kartı**  
**Bayraktar, Ahmet Murat.**  
Benign Prostat Hiperplazisinde Alfa Blokör Kullanımı ve Cinsel Fonksiyonlar /  
Ahmet Murat Bayraktar.  
Ankara : Akademisyen Yayınevi Kitabevi, 2026.  
78 s. : şekil, tablo. ; 135x210 mm.  
Kaynakça var.  
ISBN 9786253620103

**GENEL DAĞITIM**  
**Akademisyen Kitabevi A.Ş.**

Halk Sokak 5 / A Yenışehir / Ankara  
Tel: 0312 431 16 33  
siparis@akademisyen.com

www.akademisyen.com

## TEŐEKKÜR

Mesleki gelişimime katkılarıyla yolumu aydınlatan Prof. Dr.Arslan Ardıçođlu'na; bu eserin kitap haline gelmesinde sadece bir danışman deđil, aynı zamanda yardımcı editör olarak büyük emek veren Prof.Dr.Özdem Levent Özda' a katkıları için şükranlarımı sunuyorum.

Zorlu çalışma anlarını paylaştığımız dostlarım Prof.Dr.Erkan Ölçücüođlu, Doç.Dr.Mehmet Emin Şirin ve Doç.Dr Sedat Taştetur'a emekleri ve destekleri için teşekkür ediyorum.

Tüm bu süreç boyunca evdeki huzurum ve en büyük destekçim olan eşim Yeşim Şerife Bayraktar'a, varlıklarıyla güç bulduğum anneme, babama ve kardeşime sonsuz teşekkürler.

Akademik çalışmaların getirdiđi yoğunlukta ihmal ettiđim ama sevgileriyle beni her zaman ödüllendiren sevgili çocuklarım Ceren ve Kerem'e bu kitabı ithaf ediyorum.

# İÇİNDEKİLER

<b>I. GİRİŞ ve AMAÇ</b> .....	<b>1</b>
<b>II. GENEL BİLGİLER</b> .....	<b>3</b>
II. 1. Prostatın Embriyolojisi.....	3
II. 2. Prostatın Anatomisi ve Histolojisi .....	4
II. 3. Benign Prostat Hiperplazisi .....	8
II. 3. 1. BPH Epidemiyolojisi:.....	9
II. 3. 2. BPH Etiyolojisi .....	10
II. 3. 3. BPH Patofizyolojisi .....	13
II. 4. BPH Tanı Yöntemleri.....	18
II. 4. 1. Hikaye.....	19
II. 4. 2. Fizik Muayene .....	20
II. 4. 3. Laboratuvar Tetkikleri.....	21
II. 4. 4. Görüntüleme Yöntemleri.....	21
II. 4. 5. Ürodinamik Çalışmalar .....	23
II. 4. 6. Endoskopi .....	25
II. 5. BPH Tedavisi.....	25
II. 5. 1. Konservatif İzlem.....	25
II. 5. 2. Medikal Tedaviler .....	26
II. 5. 2. 1. Alfa Adrenerjik Reseptör Antagonistleri (Alfa Blokörler) .....	26
II. 5. 2. 2. 5-alfa redüktaz inhibitörleri .....	30
II. 5. 2. 3. Fitoterapi.....	32
II. 5. 3. Cerrahi Tedavi.....	33
II. 5. 3. 1. Transüretral Prostat Rezeksiyonu (TUR-P) .....	34
II. 5. 3. 2. Açık Prostatektomi .....	36

II. 5. 3. 3. Minimal İnvaziv Tedavi Metodları.....	37
<b>III. MATERYAL VE METOD .....</b>	<b>39</b>
İstatistiksel Analiz .....	41
<b>IV. BULGULAR .....</b>	<b>43</b>
<b>V. TARTIŞMA ve SONUÇ .....</b>	<b>49</b>
<b>SONUÇ .....</b>	<b>57</b>
<b>VIII. EKLER .....</b>	<b>59</b>
<b>KAYNAKLAR.....</b>	<b>65</b>

## KAYNAKLAR

1. Hoese CE, Woll EM, Burkart M, Altwein JE. Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome(BPS). *Eur Urol* 2005; 47:511-517.
2. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. *Int J Impot Res* 2000;12:305-311.
3. El-Sakka AI. Lower urinary tract symptoms in patients with erectile dysfunction: Analysis of risk factors. *J Sex Med* 2006; 3: 144-149.
4. McVary K. Lower urinary tract symptoms and sexual dysfunction: Epidemiology and pathophysiology. *BJU Int* 2006;97(2 suppl):23-28.
5. Demir O, Ozdemir I, Bozkurt O, Aslan G, Esen A. The effect of  $\alpha$ -blocker therapy on erectile functions in patients with lower urinary tract symptoms due to benign prostate hyperplasia. *Asian J of Androl* 2009; 11: 716-722
6. Kirby RS, O'Leary MP, Carson C. Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. *BJU Int.* 2005; 95: 103-109.
7. James D. Brooks, MD: Anatomy of the lower urinary tract and male genitalia. *Campbell's Urology*. Edited by Walsh PC, Retik AB, Vaughan ED, Wein AJ. Eighth Edition W.B. Saunders Company. Vol. 1: 41-81, Philadelphia,2002.
8. Moore KL. The developing human: Clinically Oriented Embryology. 4th edition, W.B. Saunders Company. 68-70,1998.
9. Shapiro E. Embryologic development of the prostate. *Urol Clin North Am* 1990; 17: 487-494.
10. Tanagho EA. Anatomy of the lower urinary tract. *Campbell's Urology* (Walsh PC, Retik AB, Stamey TA, Vaughan ED, ed). Sixth edition. Philadelphia, Saunders. Vol 1, 40-69 1992
11. McNeal JE. Regional morphology and pathology of the prostate. *Am J Clin Pathol* 1968; 49: 347-357.
12. Baydinç C.,Beytur A.Ürogenital Organların Anatomik ve Histolojik Yapısı. Temel Üroloji. Anafarta K.,Bedük Y.,Arıkan N., ed.Dördüncü Baskı. Bölüm 1:1-20,2011

13. Dixon JS, Gosling JA. Macro-anatomy of the prostate. (Kirby R, Connel JD, Fitzpatrick JM, Roehrborn CG, Boyle P) Textbook of BPH, First edition, Oxford/England. Chapt.1: 3-10,1996
14. Sigman M, Jarow JP: Male Infertility. Campbell's Urology. Edited by Walsh PC, Retik AB, Vaughan ED, Wein AJ. Eighth Edition W.B. Saunders Company, Vol.2: 1475-1481, Philadelphia,2002.
15. AUA Practice Guidelines Committe: AUA guideline on management of benign prostatic hyperplasia(2003). Chapter 1: diagnosis and treatment recommendations. J Urol, 2003; 170: 530-547.
16. Aktaş A., Çevik İ.Benign Prostat Hiperplazisi . Temel Üroloji. Anafarta K.,Bedük Y.,Arıkan N., ed.Dördüncü Baskı. Bölüm 17: 915-934.2011
17. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132:474-479.
18. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338:469-471.
19. Lytton B, Emery Jm, Harvard BM. The incidence of benign prostatic hyperplasia. J Urol 1968; 99: 639-45.
20. Ozturk A, Serel TA, Kosar A, Kecelioglu M. Prevalence of benign hypertrophy of the prostate in Turkish men hospitalized in urology. Prog Urol 2000; 10: 568-570.
21. Darras FS, Lee C, Huprikar S, Rademaker AW. Evidence for a nonandrogenic role of testis and epididimis in androgen supported growth of the rat ventral prostate. J Urol 1993; 153:2023-2030.
22. McConnell JD. Prostatic growth: New insights into hormonal regulation. Br J Urol. 1995;76.
23. Claus G, McConnell JD. Benign prostat hiperplazisinin etiyojisi, patofizyolojisi, epidemiyolojisi ve doğal seyri. Campbell Üroloji 8.baskı. Walsh PC, Retik AB, Vaughan ED, Wein AJ. Güneş Kitabevi Ltd.Şti. Ankara Cilt 2: 1297-1336, 2005.
24. Kerr, JFR, Searle, J. Deletion of Cells by Apoptosis During Castration Induced Involution in the Rat Prostate, Virchows Arch B 1973; 13.
25. Partin A, et al, Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol. 1991; 145: 405-409.
26. Cunha CR, Chung LW, Shannon JM. Hormone induced morphogenesis and growth: role of mesenchymal epithelial interactions. Recent Prog Horm Res 1983; 39: 559-598.
27. Silver RL, Wiley, EI, Davis DL, Thipgen AE,Russell DW, McConnell JD. Expresion and regulation of steroid 5-alpha reductase 2 in pros-

- tate disease. *J Urol* 1994; 152: 433-437.
28. Steiner MS. Review of peptide growth factors in Benign Prostatic Hyperplasia and Urological Malignancy. *J Urol* 1995; 153: 1085-1096.
  29. Shapiro E, Hartanto V, Lepor H. Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color asisting image analysis. *J Urol* 1992; 147: 1167-1172.
  30. Caine M. Reflections on alpha-blocker therapy for benign prostate hyperplasia. *Brit J Urol.* 1995; 75: 265.
  31. Kobayashi S, Tang R, Shapiro E, et al. Characterization of human alpha-1 adrenoceptor binding sites using radioligand receptor binding on slidemounted tissue sections. *J Urol.*1993;150:2002-2006.
  32. Schwinn DA. The role of  $\alpha$ 1-adrenergic receptor subtypes in lower urinary tract symptoms. *BJU International.* 2001;88(Suppl 2):27-34.
  33. McConnell JD, Barry MJ, Bruskewitz RC. Benign Prostatic Hyperplasia: Diagnosis and treatment. Clinical Practice Guideline. AHCPR Publication No:8. : 36-42. 1994.
  34. Herbert L, Franklin CL. Benign prostat hiperplazisinin değeriendirilmesi ve cerrahi olmayan tedavisi. Campbell Üroloji 8.baskı. Walsh PC, Retik AB, Vaughan ED, Wein AJ. Güneş Kitabevi Ltd.Şti., Ankara. Cilt 2: 1337-1378, 2005.
  35. Ezz el Din K, Kiemene LA, de Wildt MJ, Debruyne FM, de la Rosette JJ.: Correlation between uroflowmetry, prostate volume, post-void residue and lower urinary tract symptoms as measured by the International Prostate Symptom Score. *Urology* 1996; 48: 393-397.
  36. Roehrborn CG: Benign prostatic hyperplasia: Updated guidelines and new perspectives. *Am J Urol* 2004; 2 (suppl 3): 4-13,
  37. Polusen AL, Schou J, Puggard L, Torp-Pedersen S: Prostatic enlargement symptomatology and pressure flow evaluation: interrelations in patient with symptomatic BPH. *Scand J Urol Nephrol* 1994; 157: 67-73.
  38. Abrams P, Griffiths D, Höfner, et al: The urodynamic assessment of lower urinary tract symptoms (Committee 7): In: Chatalein C, Denis L, Foo K, Khoury S, McConnel J (eds). *Proceeding of 5th International Consultation on Benign Prostatic Hyperplasia.* 2001; 227-281.
  39. Arıkan N. Ürodinamik İncelemeler. Güneş Kitabevi, 145-162, 1990.
  40. Novara G, Galfano A, Gardi M, Ficarra V, Boccon-Gibod L, Artibani W: Critical Review of Guidelines for BPH Diagnosis and Treat-

- ment Strategy .European Urology Supplements 2006; 5: 418-429.
41. Andersson KE, Lepor H, Wyllie MG. Prostatic  $\alpha$ 1-adrenoreceptors and uroselectivity. *Prostate* 1997; 30: 202-215.
  42. Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. *Br J Urol* 1976; 48: 255-263.
  43. Caine M. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. *J Urol* 1986;136:1-4.
  44. Lepor H and the Multicenter Study Group. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. *Urology* 1995; 45: 406-413.
  45. Jardin A, Bensadoun H, Delauche-Cavallier MC, et al. Long term treatment of benign prostatic hypertrophy with alfuzosin: A 12-18 months assessment. *Br J Urol* 1993; 72: 615-621.
  46. Lukacs B, Blondin P, MacCarthy C, et al. Safety profile of 3 months therapy with alfuzosin in 13.389 patients suffering from benign prostatic hypertrophy. *Eur Urol* 1996; 29: 29-32.
  47. Buzelin JM, Geffriaud-Ricouard C, Delauche-Cavallier MC, et al. A double-blind placebo controlled trial of sustained-release alfuzosin in symptomatic benign prostatic hyperplasia. *J Urol* 1995;153 (suppl):274-278.
  48. Höfner K, Jones U: Alfuzosin : a clinically uroselective alpha-1 blocker . *World J Urol* 2002; 19: 405-412.
  49. Annemans I, Cleemput I, Lamotte M, McNeill A, Hargreave T: The economic impact of using alfuzosin 10mg once daily in the management of acute urinary retention in the UK: a 6- month analysis. *BJU Int.* 2005; 4: 566-571.
  50. McVary KT.: Alfuzosin for symptomatic prostatic hyperplasia: Long-term experience. *J Urology* 2006; 1: 35-42.
  51. McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. *Eur Urol* 2005; 47: 838-845.
  52. Michel CM, Chapple CR: Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL). *Eur Urol* 2006; 49: 501-509.
  53. Andersen JT, Ekman P, Wolf H, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two year placebocontrolled study. The Scandinavian BPH study group. *Urology.* 1995; 46: 631-637.
  54. Vaughan D, Imperato-McGinley J, McConnell J, et al. Long term (7 to 8- year) experience with finasteride in men with benign prostatic hyperplasia. *Urology.* 2002; 60(6):1040-1046.

55. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts the outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomised clinical trials. *Urology*. 1996;48: 398-405.
56. Marberger MJ, Andersen JT, Nickel JC, et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. *Eur Urology*. 2000;38: 563-568.
57. Andersen JT, Nickel JC, Marshall VR, et al. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. *Urology*. 1997;49: 839-845.
58. Bruskewitz R, Girman CJ, Fowler J, et al. Effect of finasteride on bother and other Health-Related Quality of Life Aspects Associated with Benign Prostatic Hyperplasia. PLESS Study Group. Proscar long-term efficacy and safety study. *Urology*. 1999; 4: 670-678.
59. Oesterling JE, Roy J, Agha A, et al. Biologic variability of prostate specific antigen and its usefulness as a marker for prostate cancer: Effects of finasteride. The Finasteride PSA Study Group. *Urology*. 1997;50: 13-18.
60. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5 alpha-reductase inhibition in human benign prostatic hyperplasia. *World J Urol*. 2002;19: 413-425.
61. Roehrborn CG, Boyle PJ, Nickel C, et al. Efficacy and safety of a dual inhibitor or 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. *Urology*. 2002;60: 434-441.
62. Andriole GL, Kirby R. Safety and tolerability of the Dual 5 alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. *Eur Urol*. 2003;44: 82-88.
63. Boyle P, Robertson C, Lowe F. Updated metaanalysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. *BJU International* 2004; 93: 751-756.
64. Buck AC. Phytotherapy for the prostate. *BJU International* 1996; 78:325-336.
65. Bayne CW, Donnelly F, Ross M. Serenoa repens : a 5 alpha reductase Tip 1 and 2 inhibitor- new evidence in a coculturel model of BPH. *Prostate* 1999; 40:232-241.
66. Nudell DM, Cattolica EV. Transurethral Prostatectomy: An update. *AUA Update series*, 2000; 19(5): 34-39.
67. Özdiler E. Endüroloji ve Girişimsel Üroadyoloji – Transüretal

- Rezeksiyon ve Diğer Transüretal Yöntemler. Temel Üroloji. Anafarta K.,Bedük Y.,Arıkan N., ed.Dördüncü Baskı. Bölüm 17:273-286.2011
68. Fitzpatrick JM, Mebust WK: Transurethral Prostatectomy. Campbell's Urology (Walsh PC, Retik AB, Wein, Vaughan ED Jr, ed). Eighth edition. Philadelphia, Saunders. Vol 2, Sect. 6, Chapt. 40, 1402-1412,2002.
  69. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of the Transurethral resection of the prostate (TURP)- Incidence, Management and Prevention. Eur Urol 2005;12:42.
  70. Madersbacher S, Marberger M. Is transurethral resection of the prostate stil justified? BJU Int1999; 83: 227-237.
  71. Merier DE,Tarpley JL, Imediegwa OO. The outcome of suprapubic prostatectomy: a contemporary series in the developing world. Urology 1995; 46: 40-44.
  72. Richard F, Lukacs B, Jardin A, *et al*: Results of an epidemiological survey in 3,500 French men aged 50 to 80 years with a special attention to urinary symptoms, quality of life and sexual function [abstract]. Eur Urol 2000; 37(suppl 2): 10.
  73. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O'Leary MP, Puppò P, Robertson C, Giuliano F. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol 2003;44: 637-649.
  74. Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary K, Mirone V, Porst H, Roehrborn CG. Critical Analysis of the Relationship Between Sexual Dysfunctions and Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. Eur Urol (in press) 2011 June; available from: URL: [http://www.europanurology.com/article/S0302-2838\(11\)00673-7/fulltext](http://www.europanurology.com/article/S0302-2838(11)00673-7/fulltext)
  75. McVary KT, Monnig W, Camps Jr JL, Young JM, Tseng L-J, Van Den Eeden G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized double-blind trial. J Urol 2007;177:1071-1077.
  76. McVary KT, Roehrborn C, Kaminetsky J, et al. Tadalafil relieves lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). J Urol 2007;177:1401-1407.
  77. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to

- benign prostatic hyperplasia. *Eur Urol* 2008;53: 1236–1244.
78. Bechara A, Romano S, Casabe' A, et al. Comparative efficacy as-sessment of tamsulosin vs. tamsulosin plus tadalafil in the treat-ment of LUTS/BPH. Pilot study. *J Sex Med* 2008;5:2170–2178.
  79. Gacci M, Vittori G, Siena G, et al. Long term safety and efficacy of combination therapy with vardenafil 10 mg and tamsulosin 0,4 mg for persistent irritative LUTS: a randomized double blind placebo controlled study. *Eur Urol Suppl* 2011;10: 123.
  80. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sil-denafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. *Eur Urol* 2007;51: 1717-1723.
  81. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. AUA Practice Guidelines Committee. *J Urol* 2003;170:530–547.
  82. Kobayashi K, Masumori N, Hisasue S, et al. Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective alpha 1A-blocker in normal volunteers. *J Sex Med* 2008; 5: 2185–2190.
  83. Hisasue SI, Furuya R, Itoh N, et al. Ejaculatory disorder induced by alpha–adrenergic receptor blockade is not retrograde ejaculation. *J Urol* 2005;173(Suppl)(290):A1069.
  84. Hellstrom WJG, Sikka SC. Effects of acute treatment with tamsulo-sin versus alfuzosin on ejaculatory function in healthy volun- teers. *J Urol* 2006;76:1529–1533.
  85. Van Dijk MM, De La Rosette JJ, Michel MC. Effects of alpha 1 ad-renoceptor antagonists on male sexual function. *Drugs* 2006; 66: 287–301.
  86. Kumar R, Nehra A, Jacobson DJ, et al. Alpha blocker use is asso-ciated with decreased risk of sexual dysfunction. *Urology* 2009;74: 82–87.
  87. Kirby RS, O'Leary MP, Carson C. Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. *BJU Int.* 2005; 95: 103–109.
  88. Van Moorselaar RJA, Hartung R, Emberton M *et al.* Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. *BJU Int.* 2005; 95: 603–608.
  89. Traish A, Kim NN, Moreland RB, Goldstein I. Role of alpha adre-nergic receptors in erectile function. *Int J Impot Res* 2000;12 (Suppl 1): 48–63.

90. Seo KK, Lee MY, Lim SW, Kim SC. Comparison of relaxation responses of cavernous and trigonal smooth muscles from rabbits by alpha1-adrenoceptor antagonists; prazosin, terazosin, doxazosin, and tamsulosin. *J Korean Med Sci* 1999; 14: 69-74.
91. Rosen R, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). *Eur Urol* 2005; 47: 824-830.
92. Kushiro T, Takahashi A, Saito F, Otsuka Y, Soma M, *et al.* Erectile dysfunction and its influence on quality of life in patients with essential hypertension. *Am J Hypertens* 2005; 18: 427-430.

akademisyen.com

ONLINE SİPARİŞ



Online Veri  
Tabanımıza Erişim



e-ISBN

9 786253 620103



AKADEMİSYEN KİTABEVİ

Halk Sokak No: 5/A Sıhhiye-Yenişehir/ANKARA

Tel: 0312 431 16 33 - 0312 432 21 84



akademisyenyayinevi



akademisyenctp